These findings were further validated by western blotting and quantitative RT-PCR analysis that revealed lower expression α-SMA gene and protein in NASH mice with myricetin treatment compared with those mice with vehicle treatment (Figures 3E,F). This evidence concerns the gene ACTA1 and metabolic dysfunction-associated steatohepatitis.